EMBRACE Vaginal Morbidity Study - Vaginal Morbidity Study

Medical University of Vienna, Austria Department of Radiotherapy0 个研究点目标入组 35 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•- Cancer of the uterine cervix suitable for curative treatment with definitive radio-(chemo)therapy including 3D image guided Brachytherapy.
•- Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix.
•- Staging according to FIGO and TNM guidelines
•- FIGO stage IB1-IIIB, without vaginal extension (stage IIA and IIIA not allowed)
•- Para-aortic metastatic nodes below L1-L2 are allowed
•- Patient informed concent
•- Ability to read, understand and fill in questionaires on quality of life and sexuality

•- Other primairy malignancies exept carcinoma in situ of the cervix and basal cell carcinoma of the skin.
•- Metastatic disease beyond para-aortic region (L1-L2)
•- Vaginal extension of primary tumor.
•- Pre-existent major vaginal morbidity.
•- Previous pelvic or abdominal radiotherapy
•- Combination of preoperative radiotherapy with surgery
•- Patients receiving BrachyTherapy only.
•- Patients receiing ExternalBeamRadioTherapy only.
•- Patients receiving neoadjuvant chemotherapy
•- Cotraindications to BrachyTherapy
•- Active infection or severe medical condition endagering treatment delivery

发起方

Medical University of Vienna, Austria Department of Radiotherapy